Role of monocytes and endothelial cells in heparin-induced thrombocytopenia

Summary

Heparin-induced thrombocytopenia (HIT) is an autoimmune disorder characterised by thrombocytopenia and thrombosis. The mechanisms leading to platelet destruction are complex and the thrombotic complications of HIT appear to be due to multiple different intravascular targets. The dual binding of HIT antibodies to platelet surface PF4/GAG complexes and to FcγRIIA likely leads to both platelet clearance and to their direct activation. Monocytes and endothelial cells bind PF4 with higher avidity than platelets and are more resistant to competitive removal of surface-bound PF4 in the presence of heparin. Binding of HIT antibodies to PF4/glycosaminoglycan complexes on the surface on these cells leads to their activation and increased procoagulant activity. Binding of higher levels of PF4 released from activated platelets to the endothelium may lead to changes of the anticoagulant properties of the glycocalyx and target the endothelial cells for HIT antibodies. Pathogenic antibodies bound to endothelial cells further promote prothrombotic conditions by a mechanism that is independent of FcγR activation, yet not completely understood. A more detailed understanding of the role of monocytes and endothelium may identify new targets for intervention to mitigate the risk of thrombosis with less impact on systemic haemostasis than current approaches to treatment for this serious disorder.

Keywords

Thrombosis - coated platelets - FcγRIIA - glycosaminoglycans - PF4

• References

• 1 Amiral J. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
• 2 Rauova L. et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107: 2346-2353.
• 3 Cines DB. et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007; 22: 31-36.
• 4 Joglekar M. et al. Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages. J Thromb Haemost 2015; 13: 1416-1427.
• 5 Rucinski B. et al. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb Haemost 1990; 63: 493-498.
• 6 Holt JC, Niewiarowski S. Biochemistry of alpha granule proteins. Semin Hematol 1985; 22: 151-163.
• 7 Kolset SO. et al. Serglycin-binding proteins in activated macrophages and platelets. J Leukoc Biol 1996; 59: 545-554.
• 8 Perin JP. et al. Characterisation and N-terminal sequence of human platelet proteoglycan. Biochem J 1988; 255: 1007-1013.
• 9 George JN, Onofre AR. Human platelet surface binding of endogenous secreted factor VIII-von Willebrand factor and platelet factor 4. Blood 1982; 59: 194-197.
• 10 Rauova L. et al. Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). J Thromb Haemost 2009; 07 (Suppl. 01) 249-252.
• 11 Handel TM. et al. Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Ann Rev Biochem 2005; 74: 385-410.
• 12 Greinacher A. et al. Characterisation of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-892.
• 13 Ihrcke NS. et al. Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today 1993; 14: 500-505.
• 14 Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001; 11: 75-82.
• 15 Gallagher JT, Walker A. Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides. Biochem J 1985; 230: 665-674.
• 16 Sugahara K. et al. Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr Opin Struct Biol 2003; 13: 612-620.
• 17 Lortat-Jacob H. et al. Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci USA 2002; 99: 1229-1234.
• 18 Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994; 04: 394-400.
• 19 Rauova L. et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010; 116: 5021-5031.
• 20 Petersen F. et al. Characterisation of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4. J Biol Chem 1999; 274: 12376-12382.
• 21 Xiao Z. et al. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood 2008; 112: 1091-1100.
• 22 Cines DB. et al. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581-589.
• 23 Visentin GP. et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
• 24 Arepally GM. et al. Characterisation of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 2000; 95: 1533-1540.
• 25 Cuker A. et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 2013; 121: 3727-3732.
• 26 Chong BH. et al. Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and FC fragments on antibody-heparin-platelet interaction. Thromb Res 1989; 55: 291-295.
• 27 Kelton JG. et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930.
• 28 Reilly MP. et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001; 98: 2442-2447.
• 29 Tutwiler V. et al. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. Blood 2016; 127: 464-472.
• 30 Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-234.
• 31 Cai Z. et al. Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nature Commun 2015; 06: 8277.
• 32 Litvinov RI. et al. Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. J Biol Chem 2013; 288: 33060-33070.
• 33 Sachais BS. et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood 2012; 120: 1137-1142.
• 34 Reilly MP. et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 2011; 117: 2241-2246.
• 35 Zhou Y. et al. Anti-miR-148a regulates platelet FcgammaRIIA signalling and decreases thrombosis in vivo in mice. Blood 2015; 126: 2871-2881.
• 36 Hughes M. et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-194.
• 37 Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10: 249-258.
• 38 Greinacher A. et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-851.
• 39 Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol 2010; 17: 53-59.
• 40 Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nature Rev Immunol 2014; 14: 392-404.
• 41 Serbina NV. et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008; 26: 421-452.
• 42 Gordon S. The macrophage: past, present and future. Eur J Immunol 2007; 37 (Suppl. 01) S9-S17.
• 43 Parish CR. The role of heparan sulphate in inflammation. Nature Rev Immunol 2006; 06: 633-643.
• 44 Greinacher A. et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395-1401.
• 45 Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001; 98: 1252-1254.
• 46 Pouplard C. et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97: 3300-3302.
• 47 Kasthuri RS. et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgammaRI. Blood 2012; 119: 5285-5293.
• 48 Lhermusier T. et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost 2011; 09: 2067-2076.
• 49 Rollin J. et al. Increased risk of thrombosis in FcgammaRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood 2015; 125: 2397-2404.
• 50 Kahn ML. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887.
• 51 Kahn ML. et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694.
• 52 Xu WF. et al. Cloning and characterisation of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95: 6642-6646.
• 53 Andre P. et al. Formation of Procoagulant Platelets in Heparin-Induced Thrombocytopenia (HIT) Follows a Unique Signalling Pathway. Blood-ASH Annual Meeting Abstracts 2011; 118: 93.
• 54 Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 03: 2185-2192.
• 55 Verhamme P, Hoylaerts MF. The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belgica 2006; 61: 213-219.
• 56 Chappell D. et al. The glycocalyx of the human umbilical vein endothelial cell: an impressive structure ex vivo but not in culture. Circ Res 2009; 104: 1313-1317.
• 57 Rao AK. et al. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983; 61: 1208-1214.
• 58 Dawes J. et al. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76.
• 59 Rybak ME. et al. Interaction of platelet factor four with cultured vascular endothelial cells. Blood 1989; 73: 1534-1539.
• 60 Busch C. et al. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 1980; 19: 129-137.
• 61 Jordan RE. et al. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem 1982; 257: 400-406.
• 62 Stern D, Nawroth P, Marcum J. et al. Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 1985; 75: 272-279.
• 63 Eslin DE. et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004; 104: 3173-3180.
• 64 Dudek AZ. et al. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C. J Biol Chem 1997; 272: 31785-31792.
• 65 Slungaard A, Key NS. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem 1994; 269: 25549-25556.
• 66 Slungaard A. et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003; 102: 146-151.
• 67 Kowalska MA. et al. Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood 2007; 110: 1903-1905.
• 68 Rauova L. et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131-138.
• 69 Suvarna S. et al. Determinants of PF4/heparin immunogenicity. Blood 2007; 110: 4253-4260.
• 70 Kowalska MA. et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood 2011; 118: 2882-2888.
• 71 Herbert JM. et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998; 80: 326-331.
• 72 Blank M. et al. Anti-platelet factor 4/heparin antibodies from patients with he-parin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002; 14: 121-129.
• 73 Hayes VM. et al. “Rolling Recruitment” of Endothelial Cell (EC) Activation in the Prothrombotic Nature of Heparin-Induced Thrombocytopenia (HIT). Blood - ASH Annual Meeting Abstracts 2011; 118: 248.
• 74 Khairy M. et al. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 2001; 85: 1090-1096.
• 75 Andre P. et al. Critical role for Syk in responses to vascular injury. Blood 2011; 118: 5000-50010.
• 76 van Eeuwijk JM. et al. The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction. Arterioscler Thromb Vasc Biol 2016 Epub ahead of print.